It should be noted that (i) most publications cited in this review do not distinguish between glioma, astrocytoma or oligodendroglioma, and consequently are referred to as “glioma” in the present review; (ii) the detailed reference of a sample or cell line to a particular subtype defined in the 2016 classification is usually not reported by the authors and therefore not mentioned in this review; (iii) the vast majority of studies that address the impact of steroid hormones or receptors on glioma use IDH1 wild-type GBM cell lines for in vitro studies or for animal xenografts. Here, IDH1 is linked to glioma.